A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD)
About this trial
This is an interventional supportive care trial for Duchenne Muscular Dystrophy (DMD) focused on measuring Duchenne Muscular Dystrophy, Corticosteroids
Eligibility Criteria
Inclusion Criteria:
- Genetically confirmed dystrophin mutation compatible with DMD phenotype. Specifically, gene deletion test positive (missing one or more exons) in the central rod domain (exons 25-60) of dystrophin, where reading frame can be predicted as 'out-of-frame' OR showing complete absence of dystrophin by muscle biopsy.
- Ages between 3 years and < 7 years
- Steroid-naïve
- Signed informed consent
Exclusion Criteria:
- Treatment with CoenzymeQ10, creatine, amino acid supplements within 3 months of study entry
- Treatment with cardiac medications: beta-blockers, digoxin, and carvedilol
- Existing medical condition or physical disability that would alter subject's motor development
- Existing medical condition that precludes the use of corticosteroids
- Inability to swallow sample tablet in bite of soft food*
- Investigator assessment that participant or family will not be compliant with treatment or study procedures
- Been on investigational DMD medication for the past 6 months
Sites / Locations
- Ann and Robert H. Lurie Children's Hospital of Chicago
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Experimental
Placebo Comparator
Placebo Comparator
Immediate Release Prednisone
Delayed Release Prednisone
Placebo-Delayed Release Prednisone
Placebo-Immediate Release Prednisone
During the entire 18 months of the protocol, these subjects will receive immediate release prednisone as a morning dose. All observations and measurements are performed the same as the other study groups.
During the entire 18 months of the protocol, these subjects will receive delayed release prednisone as an evening dose. All observations and measurements are performed the same as the other study groups.
During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the delayed release prednisone medication. All observations and measurements are performed the same as the other study groups.
During the first 6 months of the protocol, these subjects will receive placebo. After 6 months, this half of the placebo group was re-randomized to receive the immediate release corticosteroid medication. All observations and measurements are performed the same as the other study groups.